Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

73
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
73
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

137
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
137
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

100
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
100
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

445
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
445
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

86
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
86
Pulse rhythm01:30

Pulse rhythm

1.0K
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Circulation·2026
Same author

Physical activity and Brugada ECG pattern during 12-lead Holter monitoring.

The Journal of sports medicine and physical fitness·2026
Same author

Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF Trial.

Journal of the American College of Cardiology·2026
Same author

How Many CPVT Patients Need an ICD?: The Impact of Left Cardiac Sympathetic Denervation.

JACC. Clinical electrophysiology·2026
Same author

Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE.

Circulation·2026
Same author

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.

JAMA·2026
Same journal

Lipid-lowering therapies: the arrows in the quiver and future bullets.

Minerva cardiology and angiology·2026
Same journal

From population science to the utmost technical aspects: a glimpse at some of today's key cardiovascular research topics.

Minerva cardiology and angiology·2026
Same journal

Presepsin as a biomarker of coronary artery disease in type 2 diabetes along the immune-inflammatory continuum.

Minerva cardiology and angiology·2026
Same journal

Use of vericiguat in a patient with heart failure with reduced ejection fraction and transthyretin cardiac amyloidosis: a helpful therapeutic opportunity.

Minerva cardiology and angiology·2026
Same journal

Bridging cardiology and neurorehabilitation: toward integrated recovery after acute and chronic cardiac events.

Minerva cardiology and angiology·2026
Same journal

A new tool for risk stratification in transcatheter aortic valve intervention.

Minerva cardiology and angiology·2026
See all related articles

Related Experiment Video

Updated: Oct 26, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.4K

Machine learning for cardiology.

Yasir Arfat1, Gianluca Mittone2, Roberto Esposito2

  • 1Department of Computer Science, University of Turin, Turin, Italy - yasir.arfat@unito.it.

Minerva Cardiology and Angiology
|August 2, 2021
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) in cardiology is reviewed, focusing on machine learning (ML) risk scores. While adoption grows, advanced ML techniques like semi-supervised and federated learning remain underutilized.

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.8K
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.1K

Related Experiment Videos

Last Updated: Oct 26, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.4K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.8K
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.1K

Area of Science:

  • Cardiology
  • Artificial Intelligence
  • Machine Learning

Background:

  • Physicians are increasingly using artificial intelligence (AI) tools, specifically machine learning (ML) techniques, in cardiology.
  • This review focuses on ML-based risk scores commonly used in cardiovascular research, examining their assumptions, biases, merits, and shortcomings.

Purpose of the Study:

  • To review current applications of AI and ML in cardiology.
  • To analyze the adoption and effectiveness of ML-based risk scores in cardiovascular research.
  • To identify underutilized ML techniques and future research directions.

Main Methods:

  • Review of recent cardiology literature on AI and ML applications.
  • Detailed introduction to principal ML-based risk scores, explaining their function without requiring deep technical expertise.
  • Comparative analysis of ML approaches with traditional statistical methods.

Main Results:

  • ML-based risk scores are increasingly adopted in cardiology, though their frequency of use varies.
  • Neural networks are gradually being integrated, but techniques like semi-supervised and federated learning are underutilized.
  • Underutilization may stem from a lack of awareness or perceived complexity, despite their potential benefits.

Conclusions:

  • Significant potential exists for advanced ML techniques in cardiology, particularly semi-supervised and federated learning.
  • Semi-supervised learning can leverage partially labeled datasets, while federated learning enables collaborative model building across institutions.
  • Future research should explore and promote the adoption of these underutilized ML methods to advance cardiovascular research and practice.